Stock listing

Frankfurt:6L8 Pulse Biosciences, Inc Aktie

German listing (Frankfurt) of Pulse Biosciences, Inc · home listing NASDAQ:PLSE

Follow Pulse Biosciences, Inc into a list and get an email when it puts out news.

Share price · FWB:6L8

€48.60 EUR +1.40 (+3.0%)

Close on Oct 30, 2026

Day range
€48.60 – €48.60 EUROct 30, 2026
Market cap
€3.47B EURAt the close on Oct 30, 2026 · price × 71.32M shares outstanding
Pulse Biosciences, Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PLSE · Home$52.24 USD-3.24 (-5.8%)466,442$54.33$54.70$51.39$55.48Close on Oct 30, 2026
Frankfurt:6L8€48.60 EUR+1.40 (+3.0%)—€48.60€48.60€48.60€47.20Close on Oct 30, 2026
Ticker
Frankfurt:6L8
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Pulse Biosciences (NASDAQ:PLSE) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 4:30 PM ET

    Register

Replays

  • Pulse Biosciences (NASDAQ:PLSE) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Pulse Biosciences (NASDAQ:PLSE) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 4:30 PM ET

    Watch Transcript

  • Pulse Biosciences (NASDAQ:PLSE) Q4 2025 Earnings Call

    Thu, Feb 19, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

Oct 29, 2026

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

Oct 22, 2026

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Oct 14, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2026

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Oct 8, 2026

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Oct 7, 2026

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Sep 15, 2026

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Aug 6, 2026

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Jul 30, 2026

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Jul 29, 2026

All Pulse Biosciences, Inc news

Financings

  • At-the-market programme of common stock

    Aug 6, 2026

    Announced: US$75M

    Use of proceeds: Financing flexibility through key clinical and regulatory milestones

    Announced Aug 6, 2026

  • At-the-market programme of common stock

    Aug 6, 2026

    Tranche closed: US$10.7M raised

    Tranche closed Aug 6, 2026

  • Common stock on exercise of warrants

    Aug 6, 2026

    Closed: US$1.8M raised

    Closed Aug 6, 2026

Read by 6ix AI from the company's releases

Decks

Pulse Biosciences, Inc on 6ix

News releases
41 in the last 12 months · 194 in all · newest Oct 29, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Aug 6, 2026
Decks
11 decks · latest Aug 6, 2026

Where Pulse Biosciences, Inc is listed

ListingExchangeCountryCurrency
NASDAQ:PLSE · Home listingNASDAQUnited StatesUSD
gettex:6L8gettexGermanyEUR
LS Exchange:A2AMY9LS ExchangeGermanyEUR
BOATS:PLSEBOATSUnited StatesUSD
Lang & Schwarz:A2AMY9Lang & SchwarzGermanyEUR
Frankfurt:6L8 · This pageFrankfurtGermanyEUR
Tradegate:6L8TradegateGermanyEUR
Dusseldorf:6L8DusseldorfGermanyEUR
Munich:6L8MunichGermanyEUR
Stuttgart:6L8StuttgartGermanyEUR
Hamburg:6L8HamburgGermanyEUR
Hanover:6L8HanoverGermanyEUR
Xetra:6L8XetraGermanyEUR

Log in to ask 6ix AI your own questions about Pulse Biosciences, Inc.